Detalhe da pesquisa
1.
Virtual Screening in the Cloud Identifies Potent and Selective ROS1 Kinase Inhibitors.
J Chem Inf Model
; 62(16): 3832-3843, 2022 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35920716
2.
Identification and optimisation of a pyrimidopyridone series of IRAK4 inhibitors.
Bioorg Med Chem
; 63: 116729, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35439688
3.
Relating Conformational Equilibria to Conformer-Specific Lipophilicities: New Opportunities in Drug Discovery.
Angew Chem Int Ed Engl
; 61(7): e202114862, 2022 02 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34913249
4.
Skipped Fluorination Motifs: Synthesis of Building Blocks and Comparison of Lipophilicity Trends with Vicinal and Isolated Fluorination Motifs.
J Org Chem
; 86(2): 1882-1900, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33400526
5.
A Buchwald-Hartwig Protocol to Enable Rapid Linker Exploration of Cereblon E3-Ligase PROTACs*.
Chemistry
; 26(70): 16818-16823, 2020 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32706492
6.
Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors.
Bioorg Med Chem
; 28(23): 115815, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33091850
7.
Lipophilicity trends upon fluorination of isopropyl, cyclopropyl and 3-oxetanyl groups.
Beilstein J Org Chem
; 16: 2141-2150, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32952731
8.
Practical application of ligand efficiency metrics in lead optimisation.
Bioorg Med Chem
; 26(11): 3006-3015, 2018 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29655612
9.
Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4.
Bioorg Med Chem
; 26(4): 913-924, 2018 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29398441
10.
Pd-Catalyzed C-H aziridination of 3,3,5,5-tetrasubstituted piperazin-2-ones.
Org Biomol Chem
; 16(1): 53-56, 2017 Dec 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29226938
11.
An Umpolung Approach to Alkene Carboamination: Palladium Catalyzed 1,2-Amino-Acylation, -Carboxylation, -Arylation, -Vinylation, and -Alkynylation.
J Am Chem Soc
; 137(22): 7224-30, 2015 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26020544
12.
Metabolism-driven in vitro/in vivo disconnect of an oral ERÉ VHL-PROTAC.
Commun Biol
; 7(1): 563, 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38740899
13.
Development of a Series of Pyrrolopyridone MAT2A Inhibitors.
J Med Chem
; 67(6): 4541-4559, 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38466661
14.
Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human.
Bioorg Med Chem Lett
; 23(11): 3175-9, 2013 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23628336
15.
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Cancer Res
; 83(23): 3989-4004, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37725704
16.
Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists.
J Med Chem
; 66(4): 2918-2945, 2023 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36727211
17.
Optimisation of pharmacokinetic properties in a neutral series of 11ß-HSD1 inhibitors.
Bioorg Med Chem Lett
; 22(21): 6756-61, 2012 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23013933
18.
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present).
Expert Opin Ther Pat
; 32(2): 131-151, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34763600
19.
A patent review of MAT2a inhibitors (2018-2021).
Expert Opin Ther Pat
; 32(10): 1043-1053, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36043503
20.
Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.
Bioorg Med Chem Lett
; 21(24): 7310-6, 2011 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22061639